365 related articles for article (PubMed ID: 20105592)
1. Can we preoperatively risk stratify ovarian masses for malignancy?
Oltmann SC; Garcia N; Barber R; Huang R; Hicks B; Fischer A
J Pediatr Surg; 2010 Jan; 45(1):130-4. PubMed ID: 20105592
[TBL] [Abstract][Full Text] [Related]
2. Pediatric ovarian malignancy presenting as ovarian torsion: incidence and relevance.
Oltmann SC; Fischer A; Barber R; Huang R; Hicks B; Garcia N
J Pediatr Surg; 2010 Jan; 45(1):135-9. PubMed ID: 20105593
[TBL] [Abstract][Full Text] [Related]
3. Ovarian germ cell tumours: a 17-year study in a single unit.
Panteli C; Curry J; Kiely E; Pierro A; de Coppi P; Anderson J; Sebire N; Drake D
Eur J Pediatr Surg; 2009 Apr; 19(2):96-100. PubMed ID: 19360543
[TBL] [Abstract][Full Text] [Related]
4. Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics.
Antila R; Jalkanen J; Heikinheimo O
Gynecol Oncol; 2006 Apr; 101(1):97-101. PubMed ID: 16278010
[TBL] [Abstract][Full Text] [Related]
5. Thrombocytosis associated with malignant ovarian lesions within a pediatric/adolescent population.
Haddad LB; Laufer MR
J Pediatr Adolesc Gynecol; 2008 Oct; 21(5):243-6. PubMed ID: 18794018
[TBL] [Abstract][Full Text] [Related]
6. Serum C-reactive protein in the differential diagnosis of ovarian masses.
Hefler-Frischmuth K; Hefler LA; Heinze G; Paseka V; Grimm C; Tempfer CB
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):65-8. PubMed ID: 19619929
[TBL] [Abstract][Full Text] [Related]
7. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
Gadducci A; Baicchi U; Marrai R; Ferdeghini M; Bianchi R; Facchini V
Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538
[TBL] [Abstract][Full Text] [Related]
8. Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility?
Roman LD; Muderspach LI; Burnett AF; Morrow CP
J Reprod Med; 1998 May; 43(5):403-7. PubMed ID: 9610461
[TBL] [Abstract][Full Text] [Related]
9. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
10. Surgery for ovarian masses in infants, children, and adolescents: 102 consecutive patients treated in a 15-year period.
Cass DL; Hawkins E; Brandt ML; Chintagumpala M; Bloss RS; Milewicz AL; Minifee PK; Wesson DE; Nuchtern JG
J Pediatr Surg; 2001 May; 36(5):693-9. PubMed ID: 11329568
[TBL] [Abstract][Full Text] [Related]
11. Serum tumor markers.
Perkins GL; Slater ED; Sanders GK; Prichard JG
Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
[TBL] [Abstract][Full Text] [Related]
12. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
14. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
15. Ovarian malignancy in breast cancer patients with an adnexal mass.
Simpkins F; Zahurak M; Armstrong D; Grumbine F; Bristow R
Obstet Gynecol; 2005 Mar; 105(3):507-13. PubMed ID: 15738016
[TBL] [Abstract][Full Text] [Related]
16. Pediatric ovarian malignancies: how efficacious are current staging practices?
Oltmann SC; Garcia NM; Barber R; Hicks B; Fischer AC
J Pediatr Surg; 2010 Jun; 45(6):1096-102. PubMed ID: 20620302
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
18. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
19. Ovarian masses in children and adolescents - an analysis of 521 clinical cases.
Zhang M; Jiang W; Li G; Xu C
J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):e73-7. PubMed ID: 24157281
[TBL] [Abstract][Full Text] [Related]
20. Impact of surgeon specialty on ovarian-conserving surgery in young females with an adnexal mass.
Bristow RE; Nugent AC; Zahurak ML; Khouzhami V; Fox HE
J Adolesc Health; 2006 Sep; 39(3):411-6. PubMed ID: 16919804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
